Suppressive effects of PG201, an C botanical formulation, on lipopolysaccharide-induced inflammatory mediators in Raw264.7 cells

Experimental Biology and Medicine

Volumn 237, Issue 5, 2012, Pages 499-508

  Choi, Jinyong ^a   Kim, Seon Hee ^b   Kim, Sunyoung ^a,b  

^a Seoul National University   (South Korea)

^b ViroMed Co Ltd   (South Korea)

Author keywords

AP 1; Arthritis; Botanical drug; cPLA2; CREB; Cytokines; Inflammation; INOS; Macrophage; Osteoarthritis; PG201

Indexed keywords

ALCOHOL; ANTIRHEUMATIC AGENT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOHEXIMIDE; CYTOSOLIC PHOSPHOLIPASE A2; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PG 201; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; NITRIC OXIDE; PLANT EXTRACT;

ACHYRANTHES BIBENTATA; ANGELICA SINENSIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CHAENOMELIS SPECIOSA; CINNAMOMUM CASSIA; CLEMATIS CHINENSIS; CNIDIUM OFFICINALE; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; DRUG SYNTHESIS; ELEUTHEROCOCCUS SENTICOSUS; GASTRODIA ELATA; GENTIANA MACROPHYLLA; IMMUNOMODULATION; LEDEBOURIELLA SESELOIDES; MACROPHAGE; MEDICINAL PLANT; MOUSE; NONHUMAN; NORTHERN BLOTTING; OSTEOARTHRITIS; PHLOMIS UMBROSA; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; SAFFLOWER; WESTERN BLOTTING; ARACHIDONIC ACID RELEASE ASSAY; BIOASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GRIESS ASSAY; IC50; IMMUNOSUPPRESSIVE TREATMENT; MTT ASSAY; PROTEIN STABILITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; CELL LINE; CHEMOKINE CCL2; CYCLOHEXIMIDE; DINOPROSTONE; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS; PHOSPHOLIPASES A2, CYTOSOLIC; PLANT EXTRACTS; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862018920     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011203     Document Type: Article

References (43)

1. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010;6:625-35
2. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:102-10
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440
4. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33-42
5. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42
6. Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E. The role of nitric oxide in osteoarthritis. Scand J Rheumatol 2007;36:247-58
7. Abramson SB, Amin AR, Clancy RM, Attur M. The role of nitric oxide in tissue destruction. Best Pract Res Clin Rheumatol 2001;15:831-45
8. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002;46:1789-803
9. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003;33:155-67
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
11. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816-25
12. Caivano M, Cohen P. Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages. J Immunol 2000;164:3018-25
13. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-66
14. Sutcliffe AM, Clarke DL, Bradbury DA, Corbett LM, Patel JA, Knox AJ. Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1. Br J Pharmacol 2009;157:436-50
15. Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010;9:257-8
16. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41
17. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
18. Shin SS, Jin M, Jung HJ, Kim B, Jeon H, Choi JJ, Kim JM, Cho BW, Chung SH, Lee YW, Song YW, Kim S. Suppressive effects of PG201, an ethanol extract from herbs, on collagen-induced arthritis in mice. Rheumatology (Oxford) 2003;42:665-72
19. Park KC, Park EJ, Kim ER, Kim Y, Chung SH, Cho BW, Kim S, Jin M. Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-induced arthritis in rabbits. Biochem Biophys Res Commun 2005;331:1469-77
20. Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmacol 2000;129:1553-60
21. Kim D, Kim SH, Park EJ, Kang CY, Cho SH, Kim S. Anti-allergic effects of PG102, a water-soluble extract prepared from Actinidia arguta, in a murine ovalbumin-induced asthma model. Clin Exp Allergy 2009;39:280-9
22. Choi JJ, Jin M, Lee JK, Lee WY, Park YI, Han YN, Kim S. Control of cytokine gene expression by PG101, a water-soluble extract prepared from Lentinus lepideus. Biochem Biophys Res Commun 2006;339:880-7
23. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, Lee MJ, Yang CS. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004;25:1671-9
24. Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler H, Kenner L, Tschachler E, Wagner E. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther 2008;10:201
25. Fenton M. Review: transcriptional and post-transcriptional regulation of interleukin 1 gene expression. Int J Immunopharmacol 1992;14: 401-11
26. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10:2327-34
27. Gray JG, Chandra G, Clay WC, Stinnett SW, Haneline SA, Lorenz JJ, Patel IR, Wisely GB, Furdon PJ, Taylor JD. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines. Mol Cell Biol 1993;13:6678-89
28. Kuprash DV, Udalova IA, Turetskaya RL, Kwiatkowski D, Rice NR, Nedospasov SA. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol 1999;162:4045-52
29. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-16
30. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004;75:639-53
31. Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006;119:229-40
32. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46
33. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61
34. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008;26:817-23
35. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6
36. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol 2010;185:6413-9
37. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010; 23:75-93
38. Musial A, Eissa N. Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem 2001;276:24268-73
39. Walker G, Pfeilschifter J, Otten U, Kunz D. Proteolytic cleavage of inducible nitric oxide synthase (iNOS) by calpain I. BBA-Gen Subj 2001;1568:216-24
40. Mitani T, Terashima M, Yoshimura H, Nariai Y, Tanigawa Y. TGF-beta1 enhances degradation of IFN-gamma-induced iNOS protein via proteasomes in RAW 264.7 cells. Nitric Oxide 2005;13:78-87
41. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997;272:16709-12
42. Linkous A, Yazlovitskaya E. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Cell Microbiol 2010;12:1369-77
43. Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat 2010;20:1-18